4CMenB vaccine clinical trials
Counted the way a researcher would: 4CMenB vaccine with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses 4CMenB vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the 4CMenB vaccine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 29 Oct 2014 · Trumenba · BLA 125549 (FDA, Purple Book)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
50 studies that test it; most in 2014 (5)
| Year | Studies |
|---|---|
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 5 |
| 2015 | 2 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 30 · Other 20
Novartis Vaccines (10) · Pfizer (9) · GlaxoSmithKline (7) · University of Oxford (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · University of North Carolina, Chapel Hill (2) · Sanofi Pasteur, a Sanofi Company (2) · Canadian Immunization Research Network (2)
Often tested with
Tested in the same studies.
MenB-FHbp vaccine (9) · Meningococcal pentavalent vaccine (5) · Meningococcal Vaccines (4) · MenACWY (2) · Influenza Vaccines (1) · Hepatitis A Vaccines (1) · Antipyretics (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test 4CMenB vaccine.
- Dec 2026MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young AdultsPhase 4 · Emory University
- Dec 2026Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic DiseasesPhase 4 · University of Sao Paulo General Hospital
Studies
Open first, then newest update. How each study uses 4CMenB vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 50
- Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic DiseasesRecruitingPhase 4University of Sao Paulo General HospitalNCT07252804Written as Meningococcal B (Bexsero)
- Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender PersonsRecruitingPhase 4University GhentNCT06832514Written as Serogroup B meningococal vaccine
- MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young AdultsRecruitingPhase 4Emory UniversityNCT07197762Written as Trumenba
- Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.RecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT04166656Written as Trumenba®
- Meningococcal B Vaccine in Patients with AspleniaRecruitingPhase 2Medical University of ViennaNCT06025487Written as Bexsero
- A Phase 3 Study to Assess the Immune Response and Safety of rMenB+OMV NZ in Primed Healthy Participants (10 to 20 Years Old)CompletedPhase 3GlaxoSmithKlineNCT06995430Written as rMenB+OMV NZ vaccine
- Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB VaccinationCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04722003Written as Meningococcal Group B Vaccine
- Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal InfectionCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04350138Written as Meningococcal Group B Vaccine
- A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of AgeActive, not recruitingPhase 4GlaxoSmithKlineNCT06113198Written as rMenB+OMV NZ
- Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea InfectionsActive, not recruitingPhase 3Chinese University of Hong KongNCT05766904Written as 4CMenB vaccine
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria GonorrhoeaeCompletedPhase 2University of North Carolina, Chapel HillNCT05294588Written as Meningococcal Group B Vaccine
- Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and AdolescentsCompletedPhase 1/2Sanofi Pasteur, a Sanofi CompanyNCT06128733Written as Meningococcal group B vaccine
- Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)CompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT04084769Written as Meningococcal Group B vaccine (Trumenba®)
- BIYELA - Bexsero Immunisation in Young Women in AfricaActive, not recruitingPhase 3University of WashingtonNCT06446752Written as Bexsero
- Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual MenActive, not recruitingPhase 3Kirby InstituteNCT04415424Written as 4CMenB vaccine
- Pharmacists as Immunizers to Improve Coverage and Provider/Recipient SatisfactionCompletedPhase 4Canadian Immunization Research NetworkNCT02868970Written as Meningococcal B
- Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of AgeCompletedPhase 4PfizerNCT04893811Written as Trumenba
- A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy InfantsTerminatedPhase 2PfizerNCT04645966Written as Bexsero
- Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young AdultsCompletedPhase 3GlaxoSmithKlineNCT04502693Written as rMenB+OMV NZ vaccine
- A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.CompletedPhase 3PfizerNCT03135834Written as rLP2086
See all 50 studies that test 4CMenB vaccine →
Given beside what is tested · 5 — 4CMenB vaccine is usual care or a partner of the new treatment
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy InfantsCompletedPhase 3GlaxoSmithKlineNCT03621670Written as Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)
- Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of AgeCompletedPhase 3GlaxoSmithKlineNCT04318548Written as Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ)
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United KingdomCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03632720Written as Meningococcal group B vaccine
- Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSVCompletedPhase 1/2GlaxoSmithKlineNCT03636906Written as GSK's multicomponent meningococcal B vaccine
- Baby Vaccine Study (Sched3)CompletedPhase 2University of OxfordNCT02482636Written as 4-component Meningococcal B vaccine
As the comparator · 9 — what is tested is compared with 4CMenB vaccine
- A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104RecruitingPhase 1Shanghai Yuguan Biotech Co., Ltd.(Delonix Bioworks)NCT07395739Written as Bexsero®
- A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy InfantsCompletedPhase 2GlaxoSmithKlineNCT05082285Written as MenB vaccine
- A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital HerpesCompletedPhase 1/2ModernaTX, Inc.NCT06033261Written as BEXSERO
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and InfantsActive, not recruitingPhase 1/2Sanofi Pasteur, a Sanofi CompanyNCT06647407Written as Meningococcal group B vaccine
- Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and InfantsTerminatedPhase 1Sanofi Pasteur, a Sanofi CompanyNCT04825223Written as Multicomponent Meningococcal B Vaccine
- A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and AdultsCompletedPhase 1/2GlaxoSmithKlineNCT04886154Written as MenB vaccine
- Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY VaccineCompletedPhase 3GlaxoSmithKlineNCT04707391Written as MenB vaccine
- Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 YearsCompletedPhase 2GlaxoSmithKlineNCT03587207Written as rMenB+OMV NZ (Bexsero) vaccine
- A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy AdultsCompletedPhase 1GlaxoSmithKlineNCT02491463Written as Bexsero
What changed recently
From the registry's own updates since Oct 18, 2026.